CorMedix Inc. recently reported strong Q1 2026 results, with DefenCath driving a larger share of revenue and management raising full-year 2026 guidance while highlighting progress across late-stage ...
CorMedix (CRMD) drew fresh attention after reporting robust Q1 2026 results, with DefenCath playing a central role in revenue ...
Hosted on MSN
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20
CorMedix raised its second-quarter sales forecast on Monday after disclosing that its large dialysis organization (LDO) partner has started implementing DefenCath with a broader reach than previously ...
CorMedix’s CRMD lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver. The FDA approved DefenCath in late 2023 as the first and only antimicrobial ...
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...
CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents. Sales reached $104.27 million, a jump from $11.5 million a year ago, ...
The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is ...
CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), is the company’s primary source of revenues. DefenCath was approved in 2023 as the first and only antimicrobial catheter lock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results